Original Article

  1. Ubogu, EE. Amaurosis fugax associated with phencyclidine inhalation. European Neurology 2001;46:98-99.
  2. Ubogu EE, Zaidat OO, Suarez JI. Acute motor sensory axonal neuropathy associated with active systemic lupus erythematosus with anticardiolipin antibodies. JCR: Journal of Clinical Rheumatology 2001;7:326-331.
  3. Ubogu EE, Kaminski HJ. The preferential involvement of extraocular muscles in myasthenia gravis. Neuro-Ophthalmology 2001;25:219-228.
  4. Ubogu EE, Chase CM, Verrees MA, Metzger AK, Zaidat OO. Cervicomedullary junction compression caused by vertebral artery dolichoectasia and requiring surgical treatment. Case Report. Journal of Neurosurgery 2002;96:140-143.
  5. Zaidat OO, Ubogu EE. Otalgia as the sole presenting manifestation of subdural hematoma. American Journal of Otolaryngology 2002;23:177-180.
  6. Zaidat OO, Ubogu EE, Lerner AJ. Recurrent transient ischemic attacks as the initial presenting manifestation of type A aortic dissection. A case report. Annals of Vascular Surgery 2002;16:676-678 (on-line version: DOI:10.1007/s10016-001-0193-6, published on August 19, 2002).
  7. Ubogu EE, Zaidat OO. Rectus sheath hematoma complicating percutaneous endoscopic gastrostomy. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques 2002;12:430-432.
  8. Ubogu EE, Sagar SM, Lerner AJ, Maddux BN, Suarez JI, Werz M. Ketamine in refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. Epilepsy and Behavior 2003;4:70-75 (on-line version: DOI:10.1016/S1525-5050(02)00643-1, published on February 8, 2003).
  9. Ubogu EE, Katirji B. Mirtazapine-induced serotonin syndrome. Clinical Neuropharmacology 2003;26:54-57.
  10. Ubogu EE, Lindenberg JR, Werz MA. Transverse myelitis associated with acinetobacter baumanii intrathecal pump catheter-related infection. Regional Anesthesia and Pain Medicine 2003;28:470-474.
  11. Ubogu EE, Zaidat OO. Vertebrobasilar dolichoectasia diagnosed by magnetic resonance angiography and risk for stroke and death. A cohort study. Journal of Neurology, Neurosurgery and Psychiatry 2004;75:22-26.
  12. Zaidat OO, Zahuranec DB, Ubogu EE, Fernandes Filho JA, Suarez JI, Sunshine JL, Tarr RW, Mirarchi S, Noor SG, Selman WR, Landis DM. Asymptomatic middle cerebral artery stenosis diagnosed by magnetic resonance angiography. Neuroradiology 2004;46:49-53 (on-line version: DOI: 10.1007/s00234-003-1120-z, published on December 4, 2003).
  13. Ubogu EE. Complete Innervation of Extensor Digitorum Brevis by Accessory Peroneal Nerve. Neuromuscular Disorders 2005;15:562-564 (on-line version: DOI: 10.1016/j.nmd.2005.04.004, published on June 1, 2005).
  14. Ubogu EE, Hong SKT, Akman HO, DiMauro S, Katirji B, Preston DC, Shapiro BE. Adult Polyglucosan Body Disease: A Case Report of a Manifesting Heterozygote. Muscle and Nerve 2005;32:675-681 (on-line version: DOI: 10.1002/mus.20384, published on July 8, 2005).
  15. Ubogu EE, Cossoy MB, Ransohoff RM. The expression and function of chemokines involved in central nervous system inflammation. Trends in Pharmaceutical Sciences 2006;27:48-55 (on-line version: DOI: 10.1016/j.tips.2005.11.002, published on November 28, 2005).
  16. Mahad D, Callahan MK, Williams KA, Ubogu EE, Kiväsakk P, Tucky B, Kidd G, Kingsbury G, Chang A, Fox R, Mack M, Sniderman MB, Ravid R, Staugatis SM, Stins MF, Ransohoff RM. CCR2 and CCL2 modulation during blood-brain barrier migration: Relevance for their detection in the central nervous system of multiple sclerosis patients. Brain 2006;129:212-223 (on-line version: DOI: 10.1093/brain/awh655, published on October 24, 2005).
  17. Ubogu EE, Benatar M. Electrodiagnostic criteria for carpal tunnel syndrome in axonal polyneuropathy. Muscle and Nerve 2006;33:747-752 (on-line version: DOI: 10.1002/mus.20518, published on February 24, 2006).
  18. Ubogu EE, Callahan MK, Tucky BH, Ransohoff RM. Determinants of CCL5-driven mononuclear cell migration across the blood-brain barrier. Implications for therapeutically modulating neuroinflammation. Journal of Neuroimmunology 2006;179:132-144 (on-line version: DOI:10.1016/j.jneuroim.2006.06.004, published on July 20, 2006).
  19. Ubogu EE, Callahan MK, Tucky BH, Ransohoff RM. CCR5 expression on monocytes and T-cells: Modulation by transmigration across the blood-brain barrier in vitro. Cellular Immunology 2006;243:19-29 (on-line version: DOI:10.1016/j.cellimm.2006.12.001, published January 25, 2007).
  20. Ransohoff RM, Man S, Ubogu EE. “Doing the locomotion” with the multistep paradigm. Blood 2007;109:1342-1343.
  21. Man S, Ubogu EE, Ransohoff RM. Inflammatory cell migration into the central nervous system: A few new twists on an old tale. Brain Pathology 2007;17:243-250.
  22. Lai WW, Ubogu EE. Chronic inflammatory demyelinating polyradiculoneuropathy presenting as cauda equina syndrome in a diabetic. Journal of the Neurological Sciences 2007;260:267-270 (on-line version: DOI: 10.1016/j.jns.2007.04.024, published May 22, 2007).
  23. Ubogu EE, Rucker JC. Pure sensory chronic inflammatory demyelinating polyradiculopathy. Published by the American Association for Neuromuscular and Electrodiagnostic Medicine (AANEM) as an online Case Study, November 2007 (accessible via the internet at http://aanem.org/education/casestudy/cidp_1.cfm, published on November 19, 2007)
  24. Johnson K, Sargent LA, Galizio C, Ubogu EE. Interferon-α-2b/ ribavirin-induced vestibulocochlear toxicity with dysautonomia in a chronic hepatitis C patient. European Journal of Gastroenterology and Hepatology 2008; 20:1110-1114.
  25. Man S, Ubogu EE, Williams KA, Tucky B, Callahan MK, Ransohoff RM. Human brain microvascular endothelial cells and umbilical vein endothelial cells differentially facilitate leukocyte recruitment and utilize chemokines for T cell migration. Clinical and Developmental Immunology, vol. 2008, Article ID 384982, 8 pages, 2008. DOI:10.1155/2008/384982.
  26. Wolfe T, Ubogu EE, Fernandes-Filho JA, Zaidat OO. Predictors of clinical outcome and mortality in vertebrobasilar dolichoectasia diagnosed by magnetic resonance angiography. Journal of Stroke and Cerebrovascular Diseases 2008; 17:388-393.
  27. DeBrosse S, Ubogu EE, Yaniglos S, Hassan MO, Leigh RJ. Dynamic properties of eye movements in mitochondrial chronic progressive external ophthalmoplegia. Eye 2009, 23:382-388 (on-line version: DOI: 10.1038/sj.eye.6703024, published October 26, 2007).
  28. Yosef N, Xia RH, Ubogu EE. Development and characterization of a novel human in vitro blood-nerve barrier model using primary endoneurial endothelial cells. Journal of Neuropathology and Experimental Neurology 2010; 69:82-97 (on-line version DOI: 10.1097/NEN/0b013e3181c84a9, published December 11th, 2009).
  29. Xia RH, Yosef N, Ubogu EE. Clinical, electrophysiological and pathologic correlations in a severe murine experimental autoimmune neuritis model of Guillain-Barré syndrome. Journal of Neuroimmunology 2010; 219:54-63 (on-line version: DOI: 10.1016/j.jneuroim.2009.11.019, published January 19th, 2010).
  30. Xia RH, Yosef N, Ubogu EE. Dorsal caudal tail and sciatic motor nerve conduction studies in adult mice. Technical aspects and normative data. Muscle and Nerve 2010;41:850-856 (on-line version: DOI: 10.1002/mus.21588, published February 11th, 2010).
  31. Xia RH, Yosef N, Ubogu EE. Selective expression and cellular localization of pro-inflammatory chemokine ligand/receptor pairs in the sciatic nerves of a severe murine experimental autoimmune neuritis model of Guillain-Barré syndrome. Neuropathology and Applied Neurobiology 2010; 36:388-398 (on-line version: DOI: 10.1111/j.1365-2990.2010.01092.x, published as online Accepted Article on May 25th, 2010).
  32. Ubogu EE. Chemokine receptors as specific anti-inflammatory targets in peripheral nerves. Endocrine, Metabolic and Immune Disorders-Drug Targets 2011; 11:141-153.
  33. Ubogu EE, Yosef N, Xia RH, Sheikh KA. Behavioral, electrophysiological and histopathological characterization of a severe murine chronic demyelinating polyneuritis model. Journal of the Peripheral Nervous System 2012; 17: 53-61 (on-line version: DOI: 10.1111/j.1529-8027.2012. 00375.x, published March 28th, 2012).
  34. Zafar S, Ubogu E. Subacute brachial diplegia associated with West Nile virus myelitis. Muscle and Nerve 2012; 45:900–904 (on-line version: DOI: 10.1002/mus.23315, published May 10th, 2012).
  35. Yosef N, Ubogu EE. GDNF restores human blood-nerve barrier function via RET tyrosine kinase-mediated cytoskeletal reorganization. Microvascular Research 2012; 83:298-310 (on-line version: DOI: 10.1016/j.mvr.2012.01.005, published April 6th, 2012).
  36. Xia RH, Yosef N, Burns AR, Eichberg J, Ubogu EE. Isolation, purification and verification of peripheral nerve myelin derived from bovine cauda equina. Journal of Neurology and Neurophysiology 2012, S7. DOI:10.4172/2155-9562.S7-002.
  37. Yosef N, Ubogu EE. αMβ2-integrin-intercellular adhesion molecule-1 interactions drive the flow-dependent trafficking of Guillain-Barré syndrome patient derived mononuclear leukocytes at the blood-nerve barrier in vitro. Journal of Cellular Physiology 2012; 227:3857-3875 (on-line version: DOI: 10.1002/jcp.24100, published May 2nd, 2012). NIHMSID# 369459 (PubMed Central).
  38. Salisbury EA, Lazard ZW, Ubogu EE, Davis AR, Olmstead-Davis EA. Transient brown adipocyte-like cells derive from peripheral nerve progenitors in response to bone morphogenetic protein 2. Stem Cells Translational Medicine 2012; 1:874-885 (on-line version: DOI:10.5966/sctm.2012-0090, published November 26th, 2012).
  39. Ubogu EE. Translational strategies in peripheral neuroinflammation and neurovascular repair. Translational Neuroscience 2012; 3:373-383 (on-line version: DOI: 10.2478/s13380-012-0039-4). NIHMSID# 442820 (PubMed Central)
  40. Yosef N, Ubogu EE. An immortalized human blood-nerve barrier endothelial cell line for in vitro permeability studies. Cellular and Molecular Neurobiology 2013; 33:175-186 (on-line version: DOI: 10.1007/s10571-012-9882-7, published October 27th, 2012).
  41. Chiang S, Ubogu EE. The role of chemokines in Guillain-Barré syndrome. Muscle and Nerve 2013; 48:320-330 (on-line version: DOI: 10.1002/mus.23829, published February 28th, 2013).
  42. Ubogu EE. The molecular and biophysical characterization of the human blood-nerve barrier: Current concepts. Journal of Vascular Research 2013; 50:289-303 (on-line version: DOI: 10.1159/000353293, published July 6th, 2013).
  43. Lakshmana Reddy C, Yosef N, Ubogu EE. VEGF-A165 potently induces human blood-nerve barrier endothelial cell proliferation, angiogenesis and wound healing in vitro. Cellular and Molecular Neurobiology 2013; 33:789-801 (on-line version: DOI: 10.1007/s10571-013-9946-3, published May 26th, 2013).
  44. Hannawi Y, Goldsmith CE, Kass JD, Olar A, Ubogu EE, Kalkonde Y. Chronic progressive axonal polyradiculoneuropathy associated with anti-CV2/CRMP5 antibodies. Journal of Clinical Neuromuscular Disease 2013; 15:13-18 (on-line version: DOI: 10.1097/CND.0b013e3182a04538).
  45. Zafar S, Goodman JC, Ubogu EE. A male with small vessel vasculitis presenting with brachial diplegia, multiple cranial mononeuropathies and severe orthostatic hypotension in diabetes mellitus: a case report. Journal of Medical Case Reports 2013: 7:229 (on-line version: DOI: 10.1186/1752-1947-7-229, published October 1st, 2013). Article URL:http://www.jmedicalcasereports.com/content/7/1/229.
  46. Yuan F, Yosef N, Lakshmana Reddy C, Huang A, Chiang SC, Rahman Tithi H, Ubogu EE. CCR2 gene deletion and pharmacologic blockade ameliorate a severe murine experimental autoimmune neuritis model of Guillain-Barré syndrome. PLOS One 2014;9: e90463 (DOI: 10.1371/journal.pone.0090463).
  47. Yalvac M, Arnold WD, Hussain SR, Braganza C, Shontz KM, Clark KR, Walker CM, Ubogu EE, Mendell JR, Sahenk Z. VIP expressing dendritic cells protect against spontaneous autoimmune peripheral polyneuropathy. Molecular Therapy 2014; 22:1353-63 (DOI: 10.1038/mt.2014.77).
  48. Lazard ZW, Olmsted-Davis EA, Salisbury EA, Gugala Z, Sonnet C, Davis EL, Beal E 2nd, Ubogu EE, Davis AR. Osteoblasts have a neural origin in heterotopic ossification. Clinical Orthopedics and Related Research 2015; 473:2790-806 (on-line version: DOI: 10.1007/s11999-015-4323-9, published on May 6th, 2015).
  49. Ubogu EE. Inflammatory neuropathies: pathology, molecular markers and targets for specific therapeutic intervention. Acta Neuropathologica 2015; 130:445-468 (on-line version: DOI: 10.1007/s00401-015-1466-4, published on August 12th, 2015).
  50. Greathouse KM, Palladino SP, Dong C, Helton ES, Ubogu EE. Modeling leukocyte trafficking at the human blood-nerve barrier in vitro and in vivo geared towards targeted molecular therapies for peripheral neuroinflammation. Journal of Neuroinflammation 2016, 13:3 (DOI: 10.1186/s12974-015-0469-3, published on January 6th, 2016).
  51. Dong C, Palladino SP, Helton ES, Ubogu EE. The pathogenic relevance of αM-integrin in Guillain-Barré syndrome. Acta Neuropathologica 2016; 132: 739-752 (on-line version: DOI: 10.1007/s00401-016-1599-0, published on July 26th, 2016).
  52. Helton ES, Palladino SP, Ubogu EE. A novel method for measuring hydraulic conductivity at the human blood-nerve barrier in vitro. Microvascular Research 2017; 109:1-6 (on-line version: DOI: 10.1016/j.mvr.2016.08.005, published on August 31st, 2016).
  53. Bosetti F, Galis ZS, Bynoe MS et al; on behalf of the “Small Blood Vessels: Big Health Problems” Workshop Participants. “Small Blood Vessels: Big Health Problems?”: Scientific Recommendations of the National Institutes of Health Workshop. Journal of the American Heart Association 2016;5: e004389 (DOI: 10.1161/JAHA.116.004389).
  54. Dong C, Greathouse KM, Beacham RL, Palladino SP, Helton ES, Ubogu EE. Fibronectin connecting segment-1 peptide inhibits pathogenic leukocyte trafficking and inflammatory demyelination in experimental models of chronic inflammatory demyelinating polyradiculoneuropathy. Experimental Neurology 2017; 292: 35-45 (on-line version: DOI: 10.1016/j.expneurol.2017.02.012, published on February 16th, 2017).
  55. van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ; PATH study group. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology 2018;17:35-46 (on-line version: DOI: 10.1016/S1474-4422(17)30378-2, published on November 6th, 2017).
  56. Palladino SP, Helton ES, Jain P, Dong C, Crowley MR, Crossman DK, Ubogu EE. The human blood-nerve barrier transcriptome. Scientific Reports 2017; 7: 17477 (DOI: 10.1038/s41598-017-17475-y, published on December 12th, 2017. Springer Nature SharedIt link: http://rdcu.be/A7LQ)
  57. Dong C, Helton ES, Zhou P, Ouyang X, d’Anglemont de Tassigny X, Pascual A, López-Barneo J, Ubogu EE. Glial-derived neurotrophic factor is essential for blood-nerve barrier functional recovery in an experimental murine model of traumatic peripheral neuropathy. Tissue Barriers 2018; 6 (2):1-22 (on-line version: DOI: 10.1080/21688370.2018.1479570).
  58. Liu S, Dong C, Ubogu EE. Immunotherapy of Guillain-Barré syndrome. Human Vaccines & Immunotherapeutics 2018; 28:1-12 (on-line version: DOI: 10.1080/21645515.2018.1493415, published on July 12th, 2018).
  59. Dong C, Ubogu EE. GDNF enhances human blood-nerve barrier function in vitro via MAPK signaling pathways. Tissue Barriers 2018; 6 (4),1-22 (on-line version: DOI: 10.1080/21688370.2018.1546537, published on December 7th, 2018).
  60. Merkies ISJ, van Schaik IN, Léger JM, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Durn BL, Cornblath DR, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Tackenberg B, Mielke O; PRIMA Trial Investigators and the PATH Study Group. Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. Journal of the Peripheral Nervous System 2019; 24:48-55 (on-line version: DOI: 10.1111/jns.12302, published on January 22nd, 2019).
  61. Mielke O, Bril V, Cornblath DR, Lawo JP, van Geloven N, Hartung HP, Lewis RA, Merkies ISJ, Sobue G, Durn B, Shebl A, van Schaik IN; PATH study group. Restabilization treatment after IVIG withdrawal in chronic inflammatory demyelinating polyneuropathy. Results from the pre-randomization phase of the Polyneuropathy and Treatment with Hizentra® (PATH) study. Journal of the Peripheral Nervous System 2019; 24:72-79 (on-line version: DOI: 10.1111/jns.12303, published on January 22nd, 2019).
  62. Ouyang X, Dong C, Ubogu EE. In situ molecular characterization of endoneurial microvessels that form the blood-nerve barrier in normal human adult peripheral nerves. Journal of the Peripheral Nervous System 2019; 24:195-206 (on-line version: DOI: 10.1111/JNS.12326, published on May 23rd, 2019).
  63. Ubogu EE. Biology of the human blood-nerve barrier in health and disease. Special Issue: Blood-CNS and blood-nerve barriers in health and diseases and potential therapy (Guest editors: Lee, J-P and Sheikh, K). Experimental Neurology 2020; 328: 113272 (On-line version: DOI: 10.1016/j.expneurol.2020.113272, published on March 3rd, 2020).
  64. Rivner MH, Quarles BM, Pan J-X, Yu Z, Howard JF, Corse A, Dimachkie MM, Jackson C, Vu T, Small G, Lisak RP, Belsh J, Lee I, Nowak RJ, Baute V, Scelsa S, Fernandes JA, Simmons Z, Swenson A, Barohn R, Sanka RB, Gooch C, Ubogu E, Caress J, Pasnoor JM, Xu H, Mei L MD; LRP4 Research Group. The clinical features of LRP4/Agrin antibody positive myasthenia gravis: A multi-center study. Muscle and Nerve 2020; 62:333-343 (on-line version: DOI: 10.1002/mus.26985, published on June 1st, 2020).
  65. Kazamel M, Lopez M, Bebin M, Bowling K, Korf BR, Barsh GS, Cooper GM, Hurst ACE, Ubogu EE. Fibulin-5 mutation featuring Charcot Marie Tooth disease, joint hyper-laxity, and scoliosis. Neurology: Genetics 2020; 6:e476 (on-line version DOI: 10.1212/NXG.0000000000000476, eCollection 2020 August, published on June 30th, 2020).
  66. Lewis RA, Cornblath DR, Hartung HP, Sobue G, Lawo JP, Mielke O, Durn BL, Bril V, Merkies ISJ, Bassett P, Cleasby A, Ivan Schaik IN; PATH study group. Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review. Journal of the Peripheral Nervous System 2020; 25:230-237 (on-line version: DOI: 10.1111/jns.12402, published on August 5th, 2020).
  67. Dong C, Choudhary A, Ubogu EE. Glial derived neurotrophic factor: A sufficient essential molecular regulator of mammalian blood-nerve barrier tight junction formation. Neural Regeneration Research 2021; 16:1417-1418 (on-line version: DOI: 10.4103/1673-5374.300992, published on December 7th, 2020).

Letters to the Editor

  1. Ubogu EE, Katirji B. Adverse reactions to mirtazapine are unlikely to be serotonin toxicity and Mirtazapine: unable to induce serotonin toxicity? -Response. Clinical Neuropharmacology 2003;26:289-290.
  2. Ubogu EE, Verrees M, Sunshine JL, Zaidat OO. Clinical and radiological features of symptomatic cerebral perfusion failure due to carotid artery occlusion surgically corrected by extracranial-intracranial by-pass. Journal of Neurology 2004;251:613-616.
  3. Ubogu EE, Lindenberg JR, Werz M. Transverse myelitis associated with Acinetobacter baumanii intrathecal pump catheter-related infection. Where was the source of the infection? -Reply to Drs. Datta and Hurford. Regional Anesthesia and Pain Medicine 2004;29:504-505.
  4. Ubogu EE, Zaidat OO. Intracranial arterial dolichoectasia is associated with enlarged descending thoracic aorta. –Correspondence. Neurology 2005;65:1681-1682 and Neurology Online, published on 11 May 2005. (Accessible via http://www.neurology.org/cgi/eletters/63/11/2016).
  5. Khan M, Ubogu E, Alsharabati M, Salzman D, Mineishi S, Saad A. Acute myofascitis as a manifestation of chronic graft versus host disease. Muscle and Nerve 2016; 53:327-329 (on-line version: DOI: 10.1002/mus.24937, published on November 26th, 2015.